Company intelligence / Profile preview

Electroducer

Ownership: Private
Development stage: Other

Overview

Electroducer’s flagship product, the Electroducer Sleeve, integrates the Direct Wire Pacing technique to provide safer and simpler temporary cardiac pacing during endovascular procedures. Pilot study results indicate that it simplifies and secures procedures requiring temporary pacing. The device is also being evaluated for optimizing renal denervation procedures.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically, medical devices for cardiac intervention)
Industry: Surgical Medical Devices

Partnerships

Supported by partnerships with internationally renowned experts, hospitals, and industrial partners; specific names not disclosed in public sources

Beyond the preview

Go deeper on Electroducer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Electroducer.

Explore the full profile